Back to News
Dec 1, 2025 12:50 PM

Regeneron Invests $150 Million In Tessera To Advance One-Time Gene Therapy For Rare Genetic Disorder

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., on Monday announced a global collaboration to develop and commercialize TSRA-196.

• REGN is lagging behind market performance. Stay ahead of the curve here.

TSRA-196 is Tessera’s lead investigational in vivo Gene Writing program for alpha-1 antitrypsin deficiency (AATD), an inherited monogenic disease that can affect the lungs, liver or both organs.

Alpha-1 antitrypsin (AAT) deficiency is a genetic disorder that causes the body to not make enough alpha-1 antitrypsin protein, which normally protects the lungs and liver.

The rare disease currently impacts approximately 200,000 people in the U.S. ...